Nonsteroidal anti-inflammatory drugs (NSAIDs) are recommended for multimodal postoperative pain management. The purpose of this study was to evaluate the postoperative pain relief, time to ambulation, and opioid-sparing effects of flurbiprofen axetil (FA) and celecoxib (CX) after total-knee arthroplasty (TKA) surgery.A convenience sample of 300 patients was obtained using a retrospective chart review of patients who underwent TKA and received FA or CX or saline (SA) as control. Institutional review board approval was obtained, and 300 charts of patients who received TKA were reviewed. Visual analog scale (VAS) pain scores up to 6 months postoperatively, opioid requirements, range of knee motion, adverse effects, and length of hospital stay are recorded. Data were analyzed using the Pearson Chi-square where appropriate or the Fisher exact test, and all continuous variables were examined using a Wilcoxon rank test.The results of the study showed no significant differences between the 3 groups for the age, gender, American Society of Anesthesiologists class, number of patients who underwent knee surgery, weight, height, and operation duration. Patients in FA and CX demonstrated significantly reduced pain scores and less morphine consumption at rest and active motion compared to SA in 24 hours after surgery, with lower scores and less opioid requirements in the FA group. However, after 48 hours postoperatively, there are no significant differences between these groups.Intravenous application of 1 mg/kg flurbiprofen axetil twice a day and 200 mg celecoxib once a day improved analgesia and decreased morphine consumption following TKA. When the 2 active drugs were compared, it was found that flurbiprofen axetil was superior to celecoxib in terms of short-term analgesic efficacy and opioid consumption.
Patients with triple negative breast cancer (TNBC) have a higher rate of distant recurrence and a poorer prognosis than those with other breast cancer subtypes. Therefore, it is important to study the mechanism of TNBC relapse. A retrospective immunohistochemical analysis of the expression of receptor protein tyrosine phosphatase ζ (PTPRZ1) and pleiotrophin (PTN) was performed for 325 cases of breast cancer. These samples included 66 cases of luminal A breast cancer, 67 cases of luminal B breast cancer, 78 cases of Her-2-enriched breast cancer, 78 cases of TNBC and 36 cases of relapsed TNBC (RTNBC). In addition, 30 control specimens and 30 cases of metastasized lymph nodes were examined. PTPRZ1 and PTN were highly expressed in the RTNBC group. Compared with the RTNBC group, significant differences in the expression of PTPRZ1 were observed between the TNBC, BC and control groups. A significant difference was observed in the expression of PTN in the BC group (P<0.05) compared to RTNBC, and there were no significant differences in the expression of PTPRZ1 and PTN among the molecular subtypes. No significant correlation was observed between the expression of PTPRZ1, PTN, ER, PR, Her-2 and ALN and the tumor size or menopause status. No significant correlation was identified between the expression of PTPRZ1 and PTN and the expression of CD24 and CD44. In summary, high expression of PTPRZ1 may be an independent risk indicator for TNBC recurrence and metastasis.
Previous studies indicated the prognostic value of phosphatase and tensin homolog deleted on chromosome ten (PTEN) in osteosarcoma (OS). There was a great degree of inconsistency between these reports. The aim of this meta-analysis was to investigate the clinicopathological features and prognostic role of PTEN positive expression on OS. We searched NCBI PubMed, Embase, Springer, ISI Web of Knowledge, the Cochrane library, China National Knowledge Internet database (CNKI), Wanfang database, Chinese VIP database and Chinese Biological Medical Database (CBM) for relevant papers published before 28 November 2018. The eligibility of all retrieved studies assessing the relationship between PTEN expression and clinicopathological and prognostic outcomes in OS were incorporated. Pooled odds ratio (OR) and 95% confidence intervals (CIs) were used to estimate the outcomes. A total of 13 studies with 580 OS patients were involved to assess the relationship between PTEN expression and clinicopathological features of OS. PTEN positive expression was significantly associated with male (OR = 1.57, 95% CI: 1.03–2.38, P=0.035<0.05) and OS high differentiation (OR = 2.33, 95% CI: 1.26–4.29, P=0.007<0.05). Additionally, positive expressions of PTEN predict no neoplasm metastasis (OR = 5.69, 95% CI: 3.64–8.90, P<0.05). The results of our study showed that positive expression of PTEN may predict higher 5-year survival in OS with the pooled OR of 8.73 (95% CI: 4.18–18.24, P<0.05). The results from the present study suggest that positive expression of PTEN is significantly associated with male, high differentiation, no metastasis and high 5-year overall survival rate in OS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.